Prenetics Global Ltd., a leading health sciences company and parent of the IM8 premium health and longevity brand, has completed the sale of its 3PL distribution business operated by subsidiary Europa Sports Partners. The all-stock deal is valued at up to $13 million, subject to certain performance milestones. This divestiture is expected to improve Prenetics’ operating margins beginning in the second quarter of 2026, as the company will no longer incur operating losses from the Europa business, which totaled approximately $6 million in fiscal year 2025. The transaction follows Prenetics’ recent $72 million sale of ACT Genomics and reflects the company’s ongoing portfolio optimization, allowing it to concentrate resources on scaling the IM8 brand globally. The sale was finalized on January 1, 2026, and will not impact the company's 2025 financial results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9620581) on January 06, 2026, and is solely responsible for the information contained therein.